Ionis Q1 revenue up 87% to $246M; raises 2026 guidance; olezarsen sHTG peak sales view >$3B

IONIS PHARMACEUTICALS INC

2026-Q1 EPS reported -$0.56 revenue$246,091,000

Total revenue $246M (+87% YoY); GAAP operating loss $118M; non-GAAP loss $75M.
TRYNGOLZA net sales $27M; DAWNZERA $16M (+125% QoQ); royalties $58M, R&D revenue $138M incl. $95M milestones.
2026 guidance raised: total revenue $875-900M (from $800-825M); non-GAAP op. loss $425-475M (from $500-550M).
Olezarsen sHTG sNDA accepted for Priority Review (PDUFA June 30); peak net sales guidance raised to >$3B.
Zilganersen NDA for Alexander disease accepted Priority Review (PDUFA Sept 22); bepirovirsen NDA also accepted.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IONIS PHARMACEUTICALS INC reported first quarter 2026 results: revenue $246 million. Guidance raised.

Period: first quarter 2026
Revenue: $246 million
Guidance: raised
Result: reported results

Exact text from the filing

First Quarter 2026 Summary Financial Results (1): Three months ended March 31, 2026 2025 (amounts in millions) Total revenue $ 246 $ 132 Operating expenses $ 364 $ 278 Operating expenses on a non-GAAP basis $ 321 $ 249 Loss from operations $ (118 ) $ (146 ) Loss from operations on a non-GAAP basis $ (75 ) $ (117 )

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

IONIS PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001140361-26-017637

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.